MedTrace Logo

The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis

NCT01455220 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-03-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if sexual dysfunction symptoms and quality of life measures in patients with Multiple Sclerosis may be improved in patients that are prescribed Tysabri.

Conditions

Interventions

DRUG

Tysabri ® (Natalizumab)

IV, monthly

Sponsors & Collaborators

  • University of South Florida

    lead OTHER

Principal Investigators

  • Tuan Vu, MD · University of South Florida

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01455220 on ClinicalTrials.gov